GlassScriptPhysician profile
Gregory Turner Clariday
NPI 1689678641
$6,932.72
in general payments reported to CMS, 2019-2025
29 companies · $938 in 2025
The $938 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $379 · 2021: $1,233 · 2022: $805 · 2023: $1,211 · 2024: $1,458 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Gift: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.75 |
| Gift | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,507.28 | 2019-2025 | Clareon, Argos, Rocklatan |
| Abbvie INC. | $753.03 | 2022-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $489.35 | 2021-2024 | Acthar |
| Galderma Laboratories, L.P. | $357.13 | 2020-2024 | |
| Allergan, INC. | $238.03 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $210.08 | 2023-2025 | Vyzulta, Lotemax Sm, Prolensa |
| Merz North America, INC. | $206.25 | 2019 | |
| Carl Zeiss Meditec, INC. | $197.27 | 2019 | |
| Oyster Point Pharma, INC. | $178.82 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $121.86 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $102.82 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $63.04 | 2021-2022 | |
| Dompe US, INC. | $51.59 | 2023-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $45.40 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $38.75 | 2019 | |
| Amgen INC. | $37.17 | 2025 | Tepezza |
| Hologic Sales and Service, LLC | $27.89 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Haag-Streit USA, INC. | $25.00 | 2025 | |
| Ocular Therapeutix, INC. | $24.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.48 | 2021 | |
| Glaukos Corporation | $22.14 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Kala Pharmaceuticals, INC. | $20.39 | 2020 | |
| Biotissue Holdings INC. | $19.50 | 2022 | |
| Harrow Eye, LLC | $17.25 | 2025 | |
| Sight Sciences, INC. | $16.89 | 2022 | |
| Aerie Pharmaceuticals, INC. | $13.92 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.39 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Clariday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.